DrugPatentWatch Database Preview

Details for Patent: 8,668,929

Which drugs does patent 8,668,929 protect, and when does it expire?

Patent 8,668,929 protects XARTEMIS XR and is included in one NDA.

This patent has nine patent family members in eight countries.

Summary for Patent: 8,668,929

Title:	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Abstract:	Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract ("GI") of a mammal for an extended period of time.
Inventor(s):	Han; Chien-Hsuan (Sunnyvale, CA), Hou; Sui Yuen Eddie (Foster City, CA), Reid; Monica L. (San Mateo, CA)
Assignee:	Depomed, Inc. (Newark, CA)
Application Number:	13/529,960
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,668,929
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 8,668,929

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		DISCN	Yes	No	➤ Sign Up	➤ Sign Up				MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,668,929

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,394,408	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic	➤ Sign Up
8,372,432	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic	➤ Sign Up
8,377,453	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,668,929

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009223061	➤ Sign Up
Canada	2720108	➤ Sign Up
China	102105136	➤ Sign Up
European Patent Office	2262484	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,668,929

For more information try a trial or see the plans and pricing